Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2009

01-03-2009 | Preclinical Study

The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal

Authors: Ana Peixoto, Catarina Santos, Patrícia Rocha, Manuela Pinheiro, Sofia Príncipe, Deolinda Pereira, Helena Rodrigues, Fernando Castro, Joaquim Abreu, Leonor Gusmão, António Amorim, Manuel R. Teixeira

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Login to get access

Abstract

We evaluated the contribution of an Alu insertion in BRCA2 exon 3 (c.156_157insAlu) to inherited predisposition to breast/ovarian cancer in 208 families originated mostly from northern/central Portugal. We identified the c.156_157insAlu BRCA2 mutation in 14 families and showed that it accounts for more that one-fourth of deleterious BRCA1/BRCA2 mutations in breast/ovarian cancer families originated from this part of the country. This mutation originates BRCA2 exon 3 skipping and we demonstrated its pathogenic effect by showing that the BRCA2 full length transcript is derived only from the wild type allele in carriers, that it is absent in 262 chromosomes from healthy blood donors, and that it co-segregates with the disease. Polymorphic microsatellite markers were used for haplotype analysis in three informative families. In two of the three families one haplotype was shared for all but two markers, whereas in the third family all markers telomeric to BRCA2 differed from that observed in the other two. Although the c.156_157insAlu BRCA2 mutation has so far only been identified in Portuguese breast/ovarian cancer families, screening of this rearrangement in other populations will allow evaluation of whether or not it is a population-specific founder mutation and a more accurate estimation of its distribution and age.
Literature
1.
go back to reference Tonin P, Serova O, Lenoir G et al (1995) BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet 57:189PubMed Tonin P, Serova O, Lenoir G et al (1995) BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet 57:189PubMed
2.
go back to reference Durocher F, Tonin P, Shattuck-Eidens D et al (1996) Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. J Med Genet 33:814–819PubMedCrossRef Durocher F, Tonin P, Shattuck-Eidens D et al (1996) Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. J Med Genet 33:814–819PubMedCrossRef
3.
go back to reference Tonin PN, Mes-Masson AM, Futreal PA et al (1998) Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 63:1341–1351PubMedCrossRef Tonin PN, Mes-Masson AM, Futreal PA et al (1998) Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 63:1341–1351PubMedCrossRef
4.
go back to reference Dørum A, Hovig E, Tropé C et al (1999) Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or1135insA. Eur J Cancer 35:779–781PubMedCrossRef Dørum A, Hovig E, Tropé C et al (1999) Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or1135insA. Eur J Cancer 35:779–781PubMedCrossRef
5.
go back to reference Peelen T, Cornelis RS, van Vliet M et al (1996) The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1or BRCA2. Eur J Hum Genet 4:225–230PubMed Peelen T, Cornelis RS, van Vliet M et al (1996) The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1or BRCA2. Eur J Hum Genet 4:225–230PubMed
6.
go back to reference Petrij-Bosch A, Peelen T, van Vliet M et al (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17:341–345PubMedCrossRef Petrij-Bosch A, Peelen T, van Vliet M et al (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17:341–345PubMedCrossRef
7.
go back to reference Górski B, Jakubowska A, Huzarski T et al (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683–686PubMedCrossRef Górski B, Jakubowska A, Huzarski T et al (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683–686PubMedCrossRef
8.
go back to reference Konstantopoulou I, Rampias T, Ladopoulou A et al (2008) Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients. Breast Cancer Res Treat 107:431–441PubMedCrossRef Konstantopoulou I, Rampias T, Ladopoulou A et al (2008) Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients. Breast Cancer Res Treat 107:431–441PubMedCrossRef
9.
go back to reference Anagnostopoulos T, Pertesi M, Konstantopoulou I et al (2007) G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. Breast Cancer Res Treat. doi:10.1007/s10549-007-9729-y Anagnostopoulos T, Pertesi M, Konstantopoulou I et al (2007) G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. Breast Cancer Res Treat. doi:10.​1007/​s10549-007-9729-y
10.
go back to reference Rafnar T, Benediktsdottir KR, Eldon BJ et al (2004) BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. Eur J Cancer 40:2788–2793PubMedCrossRef Rafnar T, Benediktsdottir KR, Eldon BJ et al (2004) BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. Eur J Cancer 40:2788–2793PubMedCrossRef
11.
go back to reference Campos B, Díez O, Odefrey F et al (2003) Haplotype analysis of the BRCA2 9254delATCAT recurrent mutation in breast/ovarian cancer families from Spain. Hum Mutat 21:452PubMedCrossRef Campos B, Díez O, Odefrey F et al (2003) Haplotype analysis of the BRCA2 9254delATCAT recurrent mutation in breast/ovarian cancer families from Spain. Hum Mutat 21:452PubMedCrossRef
12.
go back to reference Díez O, Osorio A, Durán M et al (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22:301–312PubMedCrossRef Díez O, Osorio A, Durán M et al (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22:301–312PubMedCrossRef
13.
go back to reference Bergman A, Einbeigi Z, Olofsson U et al (2001) The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet 9:787–793PubMedCrossRef Bergman A, Einbeigi Z, Olofsson U et al (2001) The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet 9:787–793PubMedCrossRef
14.
go back to reference Peixoto A, Salgueiro N, Santos C et al (2006) BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families. Fam Cancer 5:379–387PubMedCrossRef Peixoto A, Salgueiro N, Santos C et al (2006) BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families. Fam Cancer 5:379–387PubMedCrossRef
15.
go back to reference Teugels E, De Brakeleer S, Goelen G et al (2005) De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes. Hum Mutat 26:284PubMedCrossRef Teugels E, De Brakeleer S, Goelen G et al (2005) De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes. Hum Mutat 26:284PubMedCrossRef
16.
go back to reference Machado PM, Brandão RD, Cavaco BM et al (2007) Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027–2034PubMedCrossRef Machado PM, Brandão RD, Cavaco BM et al (2007) Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027–2034PubMedCrossRef
17.
go back to reference Díez O, Gutiérrez-Enríquez S, Ramón y Cajal T et al (2007) Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families. J Clin Oncol 25:5035–5036PubMedCrossRef Díez O, Gutiérrez-Enríquez S, Ramón y Cajal T et al (2007) Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families. J Clin Oncol 25:5035–5036PubMedCrossRef
18.
go back to reference Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158PubMedCrossRef Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158PubMedCrossRef
19.
go back to reference van der Hout AH, van den Ouweland AM, van der Luijt RB et al (2006) A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat 27:654–666PubMedCrossRef van der Hout AH, van den Ouweland AM, van der Luijt RB et al (2006) A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat 27:654–666PubMedCrossRef
20.
go back to reference Claes K, Poppe B, Coene I et al (2004) BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. Br J Cancer 90:1244–1251PubMedCrossRef Claes K, Poppe B, Coene I et al (2004) BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. Br J Cancer 90:1244–1251PubMedCrossRef
21.
go back to reference Perkowska M, BroZek I, Wysocka B et al (2003) BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland. Hum Mutat 21:553–554PubMedCrossRef Perkowska M, BroZek I, Wysocka B et al (2003) BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland. Hum Mutat 21:553–554PubMedCrossRef
22.
go back to reference Shih HA, Couch FJ, Nathanson KL et al (2002) BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol 20:994–999PubMedCrossRef Shih HA, Couch FJ, Nathanson KL et al (2002) BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol 20:994–999PubMedCrossRef
23.
go back to reference Judkins T, Hendrickson BC, Deffenbaugh AM et al (2005) Single nucleotide polymorphisms in clinical genetic testing: the characterization of the clinical significance of genetic variants and their application in clinical research for BRCA1. Mutat Res 573:168–179PubMed Judkins T, Hendrickson BC, Deffenbaugh AM et al (2005) Single nucleotide polymorphisms in clinical genetic testing: the characterization of the clinical significance of genetic variants and their application in clinical research for BRCA1. Mutat Res 573:168–179PubMed
25.
go back to reference Oros KK, Leblanc G, Arcand SL et al (2006) Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. BMC Med Genet 7:23PubMedCrossRef Oros KK, Leblanc G, Arcand SL et al (2006) Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. BMC Med Genet 7:23PubMedCrossRef
Metadata
Title
The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal
Authors
Ana Peixoto
Catarina Santos
Patrícia Rocha
Manuela Pinheiro
Sofia Príncipe
Deolinda Pereira
Helena Rodrigues
Fernando Castro
Joaquim Abreu
Leonor Gusmão
António Amorim
Manuel R. Teixeira
Publication date
01-03-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-9978-4

Other articles of this Issue 1/2009

Breast Cancer Research and Treatment 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine